Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Biosimilar Antibodies

Biosimilar antibodies have emerged as valuable tools for research purposes. These antibodies, derived from genetically engineered cells, mimic the structure and function of existing therapeutic antibodies, offering cost-effective alternatives for research applications. With advancements in recombinant DNA technology and protein expression systems, monoclonal biosimilar antibodies can be produced with high specificity and reproducibility, providing researchers with reliable reagents for various experiments. The availability of recombinant biosimilar research antibodies broadens the accessibility of research-grade antibodies, facilitating scientific investigations and accelerating discoveries in diverse fields, from basic biological research to drug development and diagnostics. Discover recombinant biosimilar antibodies from antibodies-online.com.

Biosimilar Research Antibodies for Top Selling Biologicals

Below you may find the main indications, mechanisms and matching monoclonal biosimilar research antibodies for the top selling biologicals:

  1. Adalimumab
    • Therapeutic Indications: Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and others.
    • Mechanism: TNF-alpha inhibitor.
    • Biosimilar Research Antibody: Adalimumab Biosimilar Research Antibody
  2. Rituximab
    • Therapeutic Indications: Non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis.
    • Mechanism: Monoclonal antibody targeting CD20 antigen.
    • Biosimilar Research Antibody: Rituximab Biosimilar Research Antibody
  3. Trastuzumab
  4. Pembrolizumab
    • Therapeutic Indications: Various cancers, including melanoma, lung cancer, and others.
    • Mechanism: Immune checkpoint inhibitor (PD-1 inhibitor).
    • Biosimilar Research Antibody: Trastuzumab Biosimilar Research Antibody
  5. Enbrel
    • Therapeutic Indications: Rheumatoid arthritis, psoriasis, ankylosing spondylitis, and others.
    • Mechanism: TNF-alpha inhibitor.
    • Biosimilar Research Antibody: Enbrel Biosimilar Research Antibody
  6. Infliximab
    • Therapeutic Indications: Rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, ankylosing spondylitis.
    • Mechanism: TNF-alpha inhibitor.
    • Biosimilar Research Antibody: Infliximab Biosimilar Research Antibody
  7. Bevacizumab
  8. Aflibercept
    • Therapeutic Indications: Age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion.
    • Mechanism: VEGF inhibitor.
    • Biosimilar Research Antibody: Aflibercept Biosimilar Research Antibody
  9. Nivolumab
    • Therapeutic Indications: Various cancers, including melanoma, lung cancer, and others.
    • Mechanism: Immune checkpoint inhibitor (PD-1 inhibitor).
    • Biosimilar Research Antibody: Nivolumab Biosimilar Research Antibody
  10. Daratumumab

Case Study: Assessing Binding Affinity of Adalimumab Biosimilar

SPR analysis of adalimumab and its binding partners. Immobilized antibody molecules produced from either BYL or CHO cells were probed with recombinant TNFa and CD64 to show ligand and receptor binding, respectively.

Biosimilar Antibody used as benchmark: Recombinant TNF Alpha Antibody (ABIN5668145) .

Source: Biotech & Bioengineering, First published: 28 June 2023, DOI: (10.1002/bit.28461)

Case Study: Assessing Binding Affinity of Adalimumab Biosimilar

Biosimilar Antibodies in Drug Discovery

In drug discovery and subsequent development phases, biosimilar antibodies like Infliximab can be used as benchmarks in several ways:

  • Analytical Methods and Characterization: Molecular structure, post-translational modifications (PTMs), binding-specifities, and other attributes of approved biologicals are well-characterized due to their history as a reference biologic. Analytical methods and characterization techniques for new biosimilars or alternative therapy approaches can be benchmarked against those used for existing biosimilars to ensure accurate assessment of similarity.
  • Pharmacokinetics: Biosimilars can provide a reference point for comparing the pharmacokinetic properties of a biosimilar to those of the reference product. Pharmacokinetics refers to the study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Immunogenicity Assessment: Immunogenicity profiles, or the likelihood of triggering an immune response, are known from clinical experience for biosimilars that have already been introduced to the market. When developing a biosimilar or an alternative therapeutic approach, companies benchmark their immunogenicity assessment strategies against those used for existing biosimilars to ensure appropriate evaluation of potential immune reactions.
  • Clinical Trial Design: Clinical trials for biosimilar development often include a comparative efficacy and safety study, where the biosimilar is compared to the established reference product (e.g. Trastuzumab). The clinical trial design, endpoints, patient populations, and statistical analyses are often compared to existing trials of the reference product.
  • Regulatory Approval Pathways: Regulatory authorities, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), use approved biosimilars (e.g. Ranibizumab) as a reference when establishing guidelines and requirements for biosimilar approval. Developers of biosimilars can adapt their development processes and compare their data against the regulatory expectations set for existing biosimilars.

Antibody Analysis Using the Sartorius Octet® R4 System

Our service partner Rockland can help you select the best antibody or protein for your assay by providing label-free analysis using the Sartorius Octet® R4 System. Use it as part of your assay development program or as a stand-alone service. The label-free Bio-Layer Interferometry (BLI) technology enables the direct detection of specific proteins and other biomolecules in complex mixtures like crude cell culture supernatants and lysates.

BLI uses optical-based biosensors to convert biological binding reactions into signals without the use of a detection label. This allows real-time monitoring of changes that occur when an analyte binds to a ligand immobilized on a biosensor surface and eliminates the need to manipulate individual assay components. The system can be used for a wide range of analyses including kinetic analysis, quantification of IgGs and other proteins, immunoassay development, epitope binning, and ligand binding assays.

Learn More

Overall, biosimilars that are already in the clinic have a well-established history, clinical data, and regulatory status that make them valuable benchmarks in drug discovery to demonstrate the similarity, safety, and effectiveness of new drug candidates. Established and well studied biosimilars serve as gold standard when establishing new biological drugs and treatments. antibodies-online.com offers a very broad range of biosimilars and a great product range to choose from.

Julian Pampel
Julian Pampel, BSc
Content Manager at antibodies-online.com

Creative mind of antibodies-online with a keen eye for details. Proficient in the field of life-science with a passion for plant biotechnology and clinical study design. Responsible for illustrated and written content at antibodies-online as well as supervision of the antibodies-online scholarship program.

Go to author page

Explore all Biosimilar Research Antibodies

946 results:

Reactivity: Human FACS, WB, BR Host: Human Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN5668060
Reactivity: Human, Cynomolgus, Rhesus Monkey FACS, BR Host: Rabbit Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN5668119
Reactivity: Human, Cynomolgus, Rhesus Monkey FACS Host: Rabbit Monoclonal 10F381 unconjugated Recombinant Antibody
Catalog No. ABIN5668183
Reactivity: Human, Cynomolgus, Rhesus Monkey BP, FACS, IP Host: Rabbit Monoclonal hL22 unconjugated Recombinant Antibody
Catalog No. ABIN5668217
Reactivity: Human FACS, IHC, BI Host: Mouse Monoclonal B72-3 unconjugated Recombinant Antibody
Catalog No. ABIN5668023
Reactivity: Human, Cynomolgus, Rhesus Monkey FACS, WB, IF, IHC, BR Host: Human Chimeric unconjugated Recombinant Antibody
Catalog No. ABIN5668050
Reactivity: Human, Cynomolgus, Rhesus Monkey FACS, WB, IF, IHC, BR Host: Rabbit Chimeric unconjugated Recombinant Antibody
Catalog No. ABIN5668051
Reactivity: Human, Cynomolgus, Rhesus Monkey FACS, BR Host: Human Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN5668118
Reactivity: Human FACS, BR Host: Human Monoclonal C225 unconjugated Recombinant Antibody
Catalog No. ABIN5668058
Reactivity: Human FACS, IHC (p), BI Host: Human Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN5668278
  • Query: biosimilar
  • Type Primary
    • Primary
  • Target
    • CD40L (Ruplizumab Biosimilar)
    • EGFR (Cetuximab Biosimilar)
    • ErbB2/Her2 (Trastuzumab Biosimilar)
    • IL2RA (Daclizumab Biosimilar)
    • MS4A1 (Rituximab Biosimilar)
    • TNF alpha (Infliximab Biosimilar)
    • VEGF (Bevacizumab Biosimilar)
    • IL2RA (Basiliximab Biosimilar)
    • ITGA4 (Natalizumab Biosimilar)
    • ITGAL (Efalizumab Biosimilar)
    • TNF alpha (Adalimumab Biosimilar)
    • TNFSF4 (Oxelumab Biosimilar)
    • CD33 (Gemtuzumab Biosimilar)
    • CD4 (Clenoliximab Biosimilar)
    • CEACAM5 (Arcitumomab Biosimilar)
    • EGFR (Matuzumab Biosimilar)
    • IL-6R (Tocilizumab Biosimilar)
    • ITGA5 (Volociximab Biosimilar)
    • TAG-72 (Satumomab Biosimilar)
    • CCR4 (Mogamulizumab Biosimilar)
    • CD22 (Epratuzumab Biosimilar)
    • CD47 (Magrolimab Biosimilar)
    • CD80 (Galiximab Biosimilar)
    • CTLA-4 (Ipilimumab Biosimilar)
    • EGFR (Zalutumumab Biosimilar)
    • RSV (Felvizumab Biosimilar)
    • TAG-72 (Minretumomab Biosimilar)
    • TNF alpha (Humicade Biosimilar)
    • TNFSF11 (Denosumab Biosimilar)
    • sCD40L (Toralizumab Biosimilar)
    • AMHR2 (Murlentamab Biosimilar)
    • APP (Aducanumab Biosimilar)
    • AXL (Enapotamab Biosimilar)
    • C5 (Eculizumab Biosimilar)
    • C5AR1 (Avdoralimab Biosimilar)
    • CCR2 (Plozalizumab Biosimilar)
    • CD19 (Inebilizumab Biosimilar)
    • CD22 (Pinatuzumab Biosimilar)
    • CD27 (Varlilumab Biosimilar)
    • CD274 (Atezolizumab Biosimilar)
    • CD274 (Avelumab Biosimilar)
    • CD274 (Durvalumab Biosimilar)
    • CD38 (Daratumumab Biosimilar)
    • CD3E (Muromonab Biosimilar)
    • CD40 (Iscalimab Biosimilar)
    • CD45 (Apamistamab Biosimilar)
    • CD47 (Lemzoparlimab Biosimilar)
    • CD52 (Alemtuzumab Biosimilar)
    • CD70 (Vorsetuzumab Biosimilar)
    • CEACAM5 (Labetuzumab Biosimilar)
    Please use search to find more...
  • Application
    • ELISA
    • Flow Cytometry (FACS)
    • Western Blotting (WB)
    • Blocking Reagent (BR)
    • Immunohistochemistry (IHC)
    • In vivo Studies (in vivo)
    • Immunofluorescence (IF)
    • Blocking Peptide (BP)
    • Immunoprecipitation (IP)
    • Functional Studies (Func)
    • BioImaging (BI)
    • Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    • Inhibition Assay (InhA)
    • Radioimmunoassay (RIA)
    • Surface Plasmon Resonance (SPR)
    • Antagonist (Anta)
    • Depletion (Dep)
    • Neutralization (Neut)
  • Reactivity
    • Human
    • Mouse
    • Dog
    • Cynomolgus
    • Rhesus Monkey
    • Cat
    • Chimpanzee
    • Respiratory Syncytial Virus (RSV)
    • Llama
    • SARS Coronavirus-2 (SARS-CoV-2)
  • Cited in publications
  • Images available
  • Preservative free only
  • Carrier free only
  • Host
    • Mammalian Cells
    • CHO Cells
    • Human
    • Humanized
    • Mouse
    • Rabbit
    • Humanized Mouse
  • Clonality
    • Monoclonal
    • Chimeric
  • Clone
    • cA2
    • hu5c8
    • 4D5-8
    • C225
    • CE9-1
    • M200
    • R4930
    • hu1124
    • 10F381
    • B72-3
    • CDP 571
    • D2E7
    • 2F8
    • 7E3
    • HP67-6
    • IDEC-114
    • IDEC-131
    • RSHZ19
    • RhPM-1
    • hL22
    • 5C4-B8
    • H-R3
    • KW-0761
  • Binding Specificity
    • Extracellular Domain
    • AA 133-285
  • Conjugate
    • Un-conjugated
  • Isotype
    • IgG1 kappa
    • IgG1
    • IgG4
    • IgG2
    • IgG4 kappa
    • IgG1 lambda
    • IgG kappa
    • kappa
    • IgG2 kappa
    • lambda
    • IgG4 lambda
    • IgG2 lambda
    • IgG
    • IgG lambda
    • Ig Fraction
    • IgG IgA IgM Mix
    • IgG2a kappa
    • IgG2a lambda
    • IgG2b kappa
    • IgA
    • IgG2a
    • IgG2b
    • IgG3
    • IgG3 kappa
    • IgM
  • Protein Type
    • Recombinant Antibody
  • Format
    • Lyophilized
    • Liquid
  • Fragment
    • Fab fragment
    • scFv fragment
    • F(ab')2 fragment
  • Grade
    • Research Grade
  • Supplier
    • ProteoGenix
    • antibodies-online
    • Abnova
    • ACROBiosystems
You are here:
Support